BNP Paribas Financial Markets
DMAA

BNP Paribas Financial Markets’s Drugs Made In America Acquisition Corp DMAA Stock Holding History

BNP Paribas Financial Markets’s Portfolio DMAA Stock Details DMAA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$154K Buy
+14,737
New +$154K ﹤0.01% 4168

Other funds holding DMAA

KIM
Karpus Investment Management Pittsford, New York $3.21B AUM 6.83% 1-Year Est. Return
FTCM
First Trust Capital Management Chicago, Illinois $1.9B AUM 58.28% 1-Year Est. Return
MSU
Mizuho Securities USA New York $6.2B AUM 35.46% 1-Year Est. Return
GCL
Glazer Capital LLC New York $4.71B AUM 81.93% 1-Year Est. Return
WCMNY
Westchester Capital Management (New York) Valhalla, New York $2.21B AUM 26.02% 1-Year Est. Return
PAMP
Polar Asset Management Partners Toronto, Ontario, Canada $5.01B AUM 35.02% 1-Year Est. Return
WAM
Wolverine Asset Management Chicago, Illinois $10.4B AUM 4.78% 1-Year Est. Return
HCM
Highbridge Capital Management New York $3.09B AUM 31.21% 1-Year Est. Return
AC
Aristeia Capital Greenwich, Connecticut $4.82B AUM 24.91% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

BNP Paribas Financial Markets's DMAA Position: Q1 2026 in Review

BNP Paribas Financial Markets opened a new position in Drugs Made In America Acquisition Corp (DMAA) in Q1 2026: 14,737 shares worth $154K. The stake represents ﹤0.01% of the portfolio and ranks #4168 among its holdings.

39 funds tracked by Wall St. Rank hold DMAA as of Q1 2026.

  • BNP Paribas Financial Markets held 14,737 shares of Drugs Made In America Acquisition Corp worth $154K as of Q1 2026.
  • Drugs Made In America Acquisition Corp was a new BNP Paribas Financial Markets position in Q1 2026.
  • Drugs Made In America Acquisition Corp made up ﹤0.01% of BNP Paribas Financial Markets's portfolio in Q1 2026, its #4168 holding.
  • 39 funds tracked by Wall St. Rank held Drugs Made In America Acquisition Corp as of Q1 2026.

Based on BNP Paribas Financial Markets's 13F filing for Q1 2026, filed 12 May 2026.